India Emerging Infectious Disease Diagnostics Market By Infection Type (Bacterial, Viral, Fungal, Others), By Technology (Polymerase Chain Reaction (PCR), Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Others), By Region, Competition, Forecast and Opportunities, 2020-2030F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationIndia Emerging Infectious Disease Diagnostics Market By Infection Type (Bacterial, Viral, Fungal, Others), By Technology (Polymerase Chain Reaction (PCR), Immunodiagnostics, Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Others), By Region, Competition, Forecast and Opportunities, 2020-2030F
| Forecast Period | 2026-2030 |
| Market Size (2024) | USD 317.63 Million |
| Market Size (2030) | USD 559.97 Million |
| CAGR (2025-2030) | 9.87% |
| Fastest Growing Segment | Polymerase Chain Reaction (PCR) |
| Largest Market | West India |
Market Overview
India Emerging Infectious Disease Diagnostics Market was valued at USD 317.63 million by 2024 and is anticipated to reach USD 559.97 Million by 2030, with a CAGR of 9.87% during 2025-2030.
The escalating prevalence of infectious diseases, including tuberculosis, malaria, dengue, HIV/AIDS, and the recent COVID-19 pandemic, underscores the critical need for advanced diagnostic solutions. India, accounting for a significant portion of global TB cases according to the World Health Organization (WHO), highlights the urgency to invest in state-of-the-art diagnostic technologies for early detection and effective treatment.
Proactive governmental initiatives play a pivotal role in addressing this healthcare challenge. Increased healthcare expenditure and the implementation of various programs, such as the National Health Mission (NHM), aim to enhance access to quality healthcare services, particularly in rural and underserved areas. These initiatives are pivotal in promoting early disease detection and prompt treatment, thereby improving patient outcomes and alleviating strain on the healthcare infrastructure.
Also, challenges persist in ensuring widespread access to advanced diagnostic tests. High testing costs render these services unaffordable for a significant portion of the population, particularly those in low-income communities. Addressing this affordability barrier is paramount to ensure equitable access to diagnostic services for all individuals.
Key Market Drivers
Growing Prevalence of Infectious Diseases
In India, infectious diseases have long presented formidable challenges to the healthcare sector. However, the escalating prevalence of these diseases is now reshaping the landscape in unprecedented ways, particularly evident in the remarkable growth of India's Emerging Infectious Disease Diagnostics Market.
Acknowledging the urgent imperative to tackle this issue head-on, the Indian government has substantially bolstered its healthcare spending. Furthermore, it has initiated several targeted interventions to effectively combat infectious diseases. Notably, the National Health Mission (NHM) stands out as a pivotal initiative, significantly enhancing access to high-quality healthcare services, including diagnostics. These proactive measures have emerged as crucial catalysts in propelling the growth of the Infectious Disease Diagnostics Market.
Also, the COVID-19 pandemic has spotlighted the indispensable importance of swift and accurate diagnostics. Consequently, there has been an unprecedented surge in the development and adoption of advanced diagnostic technologies, such as RT-PCR tests, antigen tests, and antibody tests. These cutting-edge innovations have further accelerated the expansion of the diagnostics market, enabling early detection and efficient management of infectious diseases.
Rise in Healthcare Spending
In recent years, the Indian government has prioritized healthcare as a cornerstone of its national agenda, leading to a substantial increase in healthcare expenditure. This heightened focus on healthcare investment stems from the escalating burden of infectious diseases such as tuberculosis, malaria, dengue, HIV/AIDS, and the emergence of COVID-19 as a global health crisis. Recognizing the imperative to address these pressing health challenges, the government has committed significant resources to safeguarding the well-being of its citizens.
Also, the advent of the COVID-19 pandemic has underscored the critical necessity for rapid and accurate diagnostic tools. In response to this urgent need, there has been a considerable upsurge in healthcare spending, particularly directed towards the development and deployment of diagnostic tests like RT-PCR, antigen tests, and antibody tests. This heightened investment not only reinforces the diagnostics market but also catalyzes the emergence of more sophisticated and efficient diagnostic solutions.
Technological progress, fueled by augmented healthcare spending, assumes a central role in shaping India's diagnostics market landscape. Integration of cutting-edge technologies such as Artificial Intelligence, Machine Learning, and Genomics into diagnostic protocols has revolutionized test accuracy and efficiency, thereby elevating standards of patient care and health outcomes. Furthermore, these technological strides have opened up novel pathways for early disease detection, preventive measures, and disease management strategies.
Key Market Challenges
Surge in Resource Constraints
India is grappling with a growing burden of infectious diseases, including tuberculosis, malaria, dengue, HIV/AIDS, and the recent challenge of COVID-19. This necessitates the establishment of a robust diagnostic infrastructure that enables early detection and effective management of these diseases. However, the demand for advanced diagnostic tools has surged, straining existing resources and calling for further development.
One of the most pressing challenges is the lack of adequate healthcare infrastructure in India. Despite increased healthcare spending, there is still a shortage of diagnostic centers and laboratories, particularly in rural areas. This scarcity of infrastructure poses a significant obstacle to the accessibility and delivery of diagnostic services, thereby impeding the progress of the Emerging Infectious Disease Diagnostics Market.
In addition to infrastructure constraints, human resources present another challenge. There is a notable shortage of trained healthcare professionals who possess the expertise needed to administer and interpret advanced diagnostic tests. This deficit can lead to delayed or inaccurate diagnoses, ultimately impacting patient outcomes and the overall effectiveness of disease management.
Furthermore, financial constraints pose a substantial hurdle. While there has been an increase in healthcare spending, the high costs associated with advanced diagnostic tools often render them inaccessible to many, especially those belonging to low-income groups. This financial barrier can limit the reach of the market and hinder its potential for growth.
In light of these challenges, it is imperative to address the gaps in diagnostic infrastructure, healthcare workforce, and affordability of advanced diagnostic tools. By investing in these areas, India can strengthen its healthcare system and improve the early detection and management of infectious diseases, thereby enhancing public health outcomes.
Key Market Trends
Expansion of Molecular Diagnostics
Molecular diagnostics encompasses a diverse array of techniques utilized for analyzing biological markers like DNA and RNA within an individual's genetic makeup. This discipline holds paramount importance in detecting and managing a broad spectrum of infectious diseases, rendering it an indispensable and rapidly evolving facet of India's healthcare sector.
Several factors are driving the notable expansion of molecular diagnostics in the nation. Firstly, the escalating prevalence of infectious diseases, notably exemplified by viral outbreaks such as COVID-19, has generated an urgent demand for swift and precise diagnostic tools. Molecular diagnostics, renowned for its capability to furnish rapid and accurate results, is well-poised to address this burgeoning need, facilitating early disease identification and intervention.
Technological advancements have catalyzed significant strides in the realm of molecular diagnostics, further propelling its growth trajectory. Innovations encompassing the development of state-of-the-art rapid testing kits and AI-driven diagnostic solutions have revolutionized the speed, accuracy, and accessibility of diagnostic procedures. These technological breakthroughs empower healthcare professionals to effectively discern and monitor diseases, consequently augmenting patient outcomes and public health.
Also, the ongoing COVID-19 pandemic has underscored the paramount significance of molecular diagnostics in safeguarding public health. The imperative for expeditious and precise identification of the virus, coupled with the imperative to monitor its dissemination and manage afflicted individuals, has precipitated an unprecedented surge in demand for molecular diagnostic tests. This surge in demand has further spurred the market's expansion, prompting continual research and development endeavors aimed at refining and optimizing molecular diagnostic methodologies.
Segmental Insights
Infection Type Insights
Based on the category of infection type, the bacterial segment emerged as the dominant player in the Indian market for emerging infectious disease diagnostics in 2024. India's high population density, coupled with often inadequate sanitation and hygiene practices, creates an environment that is highly conducive to the spread of bacterial diseases. These conditions, combined with the tropical climate prevalent in many parts of the country, provide an ideal breeding ground for bacteria, leading to a higher incidence of bacterial infections.
Furthermore, the rapid urbanization in India has led to overcrowded cities, where infectious diseases, particularly those caused by bacteria, can spread rapidly. Tuberculosis, typhoid, and cholera, which are bacterial infections, are particularly common in these densely populated areas.
In addition to these challenges, antibiotic resistance has emerged as a significant issue in India. The misuse and overuse of antibiotics have resulted in the development of drug-resistant strains of bacteria, making the treatment of bacterial diseases more challenging than ever before. As a result, advanced diagnostic tests are becoming increasingly necessary to identify the specific bacteria causing the infection and to determine the most effective treatment options.
Regional Insights
West India emerged as the dominant player in the India Emerging Infectious Disease Diagnostics Market in 2024, holding the largest market share in terms of value. West India, home to major cities like Mumbai and Pune, has a high population density, with a large number of people residing in a relatively small area. This concentrated population creates a unique healthcare landscape, with specific challenges and opportunities for diagnostic services. The demand for diagnostic services is particularly high in densely populated areas due to the increased risk of infectious diseases spreading rapidly.
In response to the high population density and the demand for diagnostic services, West India has developed a robust healthcare infrastructure. The region boasts a significant number of hospitals, diagnostic centers, and research institutions, all working together to provide comprehensive and advanced diagnostic capabilities. This infrastructure plays a pivotal role in the region's dominance in the diagnostics market, as it ensures accessibility and quality in healthcare services.
Moreover, the presence of renowned research institutes in West India further promotes advancements in diagnostic technologies. These institutes engage in cutting-edge research and development, fostering innovation and driving the evolution of diagnostic techniques. As a result, West India has become a hub for biotechnology and clinical diagnostics, industries that are closely linked with infectious disease diagnostics. The synergistic relationship between these industries and the region's strong healthcare infrastructure creates a conducive environment for the growth and development of the diagnostics market.
Recent Development
- In February 2023, Thermo Fisher Scientific Inc. andMylab, a leading biotech company, announced a strategic collaboration todevelop and produce advanced test kits for infectious diseases. Thispartnership aims to leverage Thermo Fisher's expertise in molecular diagnosticsand Mylab's cutting-edge technology to address the growing need for accurateand efficient testing solutions.
- In 2023, the Food and Drug Administration(FDA) granted emergency use authorization for the Xpert Mpox test developed byCepheid, a subsidiary of DANAHER CORPORATION. This highly reliable and rapiddiagnostic test is designed to detect and identify a wide range of infectiouspathogens, providing crucial information for timely and effective patientmanagement.
Key Market Players
- AbbottIndia Ltd.
- Becton, Dickinson and Company
- bioMérieuxIndia Private Limited
- Bio-Radlaboratories Inc.
- Danaher Corporation
- RocheProducts (India) Pvt. Ltd.
| By Infection Type | By Technology | By Region |
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy